Literature DB >> 10430417

Founder mutations and the high prevalence of myotonia congenita in northern Finland.

H Papponen1, T Toppinen, P Baumann, V Myllylä, J Leisti, H Kuivaniemi, G Tromp, R Myllylä.   

Abstract

OBJECTIVE AND
BACKGROUND: To find an explanation at the molecular level for the high prevalence of myotonia congenita in northern Finland and the exceptional pattern of inheritance of the disease in many families, and to study genotype-phenotype correlation in the patients.
METHODS: Forty-six patients with myotonia congenita and 16 unaffected relatives from 24 families were studied. All 23 exons and their flanking regions of the gene for the chloride channel protein (ClC-1) were sequenced from at least one patient from all families.
RESULTS: There were three different mutations of ClC-1 in the patients: one in exon 11, a T-to-G transversion that resulted in the substitution of cysteine for phenylalanine at amino acid position 413 (F413C); one in exon 15, a C-to-T transition that resulted in the substitution of valine for alanine at amino acid position 531 (A531V); and one in exon 23, a C-to-T transition that resulted in the substitution of a stop codon for an arginine codon at amino acid position 894 (R894X).
CONCLUSIONS: Molecular studies showed that even in families with apparent dominant inheritance, the actual mode of inheritance was autosomal recessive. This was explained not only by the observed consanguinity in some families but by an enrichment of three different mutations of the ClC-1 gene and a consequent high number of compound heterozygotes in the population. One of the mutations is unique to northern Finland. The conspicuous enrichment of the mutations is likely due to the founder effect and isolation by distance, as in other diseases in the Finnish heritage.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10430417     DOI: 10.1212/wnl.53.2.297

Source DB:  PubMed          Journal:  Neurology        ISSN: 0028-3878            Impact factor:   9.910


  20 in total

1.  Functional complementation of truncated human skeletal-muscle chloride channel (hClC-1) using carboxyl tail fragments.

Authors:  Weiping Wu; Grigori Y Rychkov; Bernard P Hughes; Allan H Bretag
Journal:  Biochem J       Date:  2006-04-01       Impact factor: 3.857

2.  High frequency of co-segregating CLCN1 mutations among myotonic dystrophy type 2 patients from Finland and Germany.

Authors:  T Suominen; B Schoser; O Raheem; S Auvinen; M Walter; R Krahe; H Lochmüller; W Kress; B Udd
Journal:  J Neurol       Date:  2008-09-24       Impact factor: 4.849

3.  Consanguinity, endogamy, and genetic disorders in Tunisia.

Authors:  Nizar Ben Halim; Nissaf Ben Alaya Bouafif; Lilia Romdhane; Rym Kefi Ben Atig; Ibtissem Chouchane; Yosra Bouyacoub; Imen Arfa; Wafa Cherif; Sonia Nouira; Faten Talmoudi; Khaled Lasram; Sana Hsouna; Welid Ghazouani; Hela Azaiez; Leila El Matri; Abdelmajid Abid; Neji Tebib; Marie-Françoise Ben Dridi; Salem Kachboura; Ahlem Amouri; Mourad Mokni; Saida Ben Arab; Koussay Dellagi; Sonia Abdelhak
Journal:  J Community Genet       Date:  2012-12-04

4.  Clinical Utility Gene Card for: autosomal dominant myotonia congenita (Thomsen Disease).

Authors:  David J Coote; Mark R Davis; Macarena Cabrera; Merrilee Needham; Nigel G Laing; Kristen J Nowak
Journal:  Eur J Hum Genet       Date:  2018-04-26       Impact factor: 4.246

Review 5.  Channelopathies of skeletal muscle excitability.

Authors:  Stephen C Cannon
Journal:  Compr Physiol       Date:  2015-04       Impact factor: 9.090

6.  New immunohistochemical method for improved myotonia and chloride channel mutation diagnostics.

Authors:  Olayinka Raheem; Sini Penttilä; Tiina Suominen; Mika Kaakinen; James Burge; Andrea Haworth; Richa Sud; Stephanie Schorge; Hannu Haapasalo; Satu Sandell; Kalervo Metsikkö; Michael Hanna; Bjarne Udd
Journal:  Neurology       Date:  2012-11-14       Impact factor: 9.910

7.  Nondystrophic myotonia: challenges and future directions.

Authors:  Jaya R Trivedi; Stephen C Cannon; Robert C Griggs
Journal:  Exp Neurol       Date:  2013-12-18       Impact factor: 5.330

Review 8.  Skeletal Muscle Channelopathies.

Authors:  Lauren Phillips; Jaya R Trivedi
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

Review 9.  The non-dystrophic myotonias: molecular pathogenesis, diagnosis and treatment.

Authors:  E Matthews; D Fialho; S V Tan; S L Venance; S C Cannon; D Sternberg; B Fontaine; A A Amato; R J Barohn; R C Griggs; M G Hanna
Journal:  Brain       Date:  2009-11-16       Impact factor: 13.501

10.  Prevalence study of genetically defined skeletal muscle channelopathies in England.

Authors:  Alejandro Horga; Dipa L Raja Rayan; Emma Matthews; Richa Sud; Doreen Fialho; Siobhan C M Durran; James A Burge; Simona Portaro; Mary B Davis; Andrea Haworth; Michael G Hanna
Journal:  Neurology       Date:  2013-03-20       Impact factor: 9.910

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.